Keep up-to-date with the latest access to medicines news and research, plus interviews and opinion from our partners and other experts, and videos and photo stories of our work.
News
-
10th December Human Rights Day 2024: Achieving Equity in HIV Treatment and Prevention
On this Human Rights Day, the Global Network of People Living with HIV (GNP+) and the International Treatment Preparedness Coalition...
-
‘HIV Transmission Can be Stopped’: Leading HIV Researchers Make the Case for Compulsory Licensing of Lenacapavir
Lenacapavir (LEN), a groundbreaking, long-acting antiretroviral, has prevented nearly all HIV infections in clinical trials. LEN could be the answer...
-
Civil Society Groups Unite to Monitor the 4th Round of Thailand-EU FTA Negotiation
Grave concerns over expensive medicines, the universal health coverage scheme at risk, unsafe second-hand medical devices, farmers’ increasing debts &...
-
MMA Partner VNP+ Opposes Patent Application Which Would Limit Access to Long-Acting Cabotegravir
Vietnam’s Network of People Living With HIV (VNP+), a Make Medicines Affordable (MMA) partner, is working to improve access to, and affordability...
-
Thai HIV Advocacy Group Challenges Gilead’s and Janssen’s Patent Extension Bid, Citing Evergreening Tactics
The Thai Network of People Living with HIV/AIDS (TNP+) filed an opposition to a patent application filed by the U.S.-based pharmaceutical giant...
-
Global South Leaders Condemn Gilead’s Restrictive License on HIV Prevention Breakthrough
Civil society organizations across the Global South are blasting the U.S.-based pharmaceutical company Gilead Sciences for its lenacapavir (LEN) voluntary...
-
Indonesian Advocates Challenge Big Pharma’s Patent of HIV Prevention and Treatment Lenacapavir
Indonesia AIDS Coalition (IAC), a community-based organization advocating on HIV-related issues, filed a post-grant opposition against the secondary (selection) patent...
-
Why the World Can’t Trust Pharmaceutical Companies to Ensure Global Access to Essential Medicines
ITPC Global’s reaction to Gilead’s voluntary licence on lenacapravir: Gilead’s announcement of their voluntary license for lenacapavir—a groundbreaking, long-acting HIV...
-
Patent Applications for HIV Prevention Drug Opposed in India: Vulnerable Group Seeks to Protect Generic Competition to Lower Prices of HIV Prevention Drug Lenacapavir
New Delhi, 18 September 2024 – The Indian Patent Office is set to hear the objections of Sankalp Rehabilitation Trust...
-
HIV Community-Based Organizations are Fighting Patent Monopolies on Lenacapavir
Despite the world’s efforts, there have been over a million new cases of HIV each year. Lenacapavir (LEN), a long-acting...
-
ITPC Sounds Alarm to Prevent Mpox Treatment Disparities as WHO Declares Global Health Emergency
July 15, 2024 — ITPC Global welcomes the World Health Organization’s (WHO) declaration of the current mpox upsurge as a Public...
-
Ending the Epidemic Could Cost Under $40 (per person, per year) – treatment activists say at AIDS2024
Munich, 23 July 2024 – Despite global efforts to end HIV and AIDS, the epidemic has been persistent. In 2022,...
